cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Allovir Inc
6 own
4 watching
Current Price
$0
$0.66
(16.67%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
369.97M
52-Week High
52-Week High
10.29
52-Week Low
52-Week Low
3.17
Average Volume
Average Volume
0.13M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization369.97M
icon52-Week High10.29
icon52-Week Low3.17
iconAverage Volume0.13M
iconDividend Yield--
iconP/E Ratio--
What does the Allovir Inc do?
We are a leading late clinical-stage cell therapy company developing highly innovative allogeneic T cell therapies to treat and prevent devastating viral diseases. Our innovative and proprietary virus-specific T cell, or VST, therapy platform allows us to generate off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. --- We were formed in August 2013 under the laws of the state of Delaware under the name AdCyte LLC. In July 2014, we changed our name to ViraCyte LLC. In September 2018, we converted from a Delaware limited liability company to a Delaware corporation and changed our name to ViraCyte, Inc. In May 2019, we changed our name to AlloVir, Inc. Our principal executive offices are located at 139 Main Street, Suite 500, Cambridge, MA 02142, and our phone number is 617-433-2605. We have three wholly-owned subsidiaries, AlloVir International Designated Activity Company, AlloVir Securities Corporation and AlloVir Italia S.R.L., each of which was formed in 2019. Our website address is www.AlloVir.com.
Read More
How much money does Allovir Inc make?
News & Events about Allovir Inc.
TipRanks Financial Blog
1month ago
Morgan Stanley analyst Michael Ulz maintained a Buy rating on AlloVir (ALVR Research Report) yesterday and set a price target of $20.00. The comp... Morgan Stanley analyst Michael Ulz maintained a Buy rating on AlloVir (ALVR Research R...
Business Wire
4 months ago
AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage, allogeneic T-cell immunotherapy company, today announced the companys 2023 priorities and anticipated future milestones across its pipeline of virus-specific T cell therapies, including its lead investigational therapy posoleucel. These updates...
Business Wire
7 months ago
AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that final data from the Phase 2 study of posoleucel for the prevention of clinically significant infections or diseases by multiple viruses following allogeneic hematopoietic cell...
Business Wire
12 months ago
AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced preliminary, blinded data from an ongoing Phase 2 study of posoleucel, an investigational, allogeneic, off-the-shelf, multi-virus-specific T cell (VST) therapy, for the treatment of BK...
Ticker Report
1 year ago
Shares of AlloVir, Inc. (NASDAQ:ALVR Get Rating) gapped up before the market opened on Wednesday . The stock had previously closed at $5.41, but opened at $7.29. AlloVir shares last traded at $8.25, with a volume of 885,061 shares trading hands. Several equities analysts recently issued ...
Frequently Asked Questions
Frequently Asked Questions
What is Allovir Inc share price today?
plus_minus_icon
Can Indians buy Allovir Inc shares?
plus_minus_icon
How can I buy Allovir Inc shares from India?
plus_minus_icon
Can Fractional shares of Allovir Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Allovir Inc stocks?
plus_minus_icon
What is today’s traded volume of Allovir Inc?
plus_minus_icon
What is today’s market capitalisation of Allovir Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Allovir Inc?
plus_minus_icon
What percentage is Allovir Inc down from its 52-Week High?
plus_minus_icon
What percentage is Allovir Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.66
(16.67%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
SCHOLAR ROCK HOLDING CORP
SCHOLAR ROCK HOLDING CORP
$6.40
$0.13 (2.07 %)
CABALETTA BIO INC
CABALETTA BIO INC
$11.76
$0.61 (5.47 %)
ALX ONCOLOGY HOLDINGS INC
ALX ONCOLOGY HOLDINGS INC
$8.37
$0.05 (0.60 %)
Chemomab Therapeutics Ltd
Chemomab Therapeutics Ltd
$1.69
$-0.04 (-2.31 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
SCHOLAR ROCK HOLDING CORP
SCHOLAR ROCK HOLDING CORP
$6.40
$0.13 (2.07 %)
CABALETTA BIO INC
CABALETTA BIO INC
$11.76
$0.61 (5.47 %)
ALX ONCOLOGY HOLDINGS INC
ALX ONCOLOGY HOLDINGS INC
$8.37
$0.05 (0.60 %)
Chemomab Therapeutics Ltd
Chemomab Therapeutics Ltd
$1.69
$-0.04 (-2.31 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00